SAFETY DATA SHEET

Version 3.4 Revision Date 02/27/2016 Print Date 11/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : 1-Ethyl-3-methylimidazolium hexafluorophosphate

CAS-No. : 155371-19-0

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Synthesis of substances

1.3 Details of the supplier of the safety data sheet

Company : Sigma-Aldrich

3050 Spruce Street SAINT LOUIS MO 63103

USA

Telephone : +1 800-325-5832 Fax : +1 800-325-5052

1.4 Emergency telephone number

Emergency Phone # : +1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Not a hazardous substance or mixture.

2.2 GHS Label elements, including precautionary statements

Not a hazardous substance or mixture.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Synonyms : EMIMPF₆

Formula : $C_6H_{11}F_6N_2P$ Molecular weight : 256.13 g/mol CAS-No. : 155371-19-0

No components need to be disclosed according to the applicable regulations.

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice

Hydrofluoric (HF) acid burns require immediate and specialized first aid and medical treatment. Symptoms may be delayed up to 24 hours depending on the concentration of HF. After decontamination with water, further damage can occur due to penetration/absorption of the fluoride ion. Treatment should be directed toward binding the fluoride ion as well as the effects of exposure. Skin exposures can be treated with a 2.5% calcium gluconate gel repeated until burning ceases. More serious skin exposures may require subcutaneous calcium gluconate except for digital areas unless the physician is experienced in this technique, due to the potential for tissue injury from increased pressure.

Absorption can readily occur through the subungual areas and should be considered when undergoing decontamination. Prevention of absorption of the fluoride ion in cases of ingestion can be obtained by giving milk, chewable calcium carbonate tablets or Milk of Magnesia to conscious victims. Conditions such as hypocalcemia, hypomagnesemia and cardiac arrhythmias should be monitored for, since they can occur after exposure.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration.

In case of skin contact

Wash off with soap and plenty of water. First treatment with calcium gluconate paste.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

No data available

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Avoid dust formation. Avoid breathing vapours, mist or gas.

For personal protection see section 8.

6.2 Environmental precautions

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection. For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Store under inert gas. Moisture sensitive.

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

8.2 Exposure controls

Appropriate engineering controls

General industrial hygiene practice.

Personal protective equipment

Eye/face protection

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body Protection

Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific work-place., The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

a) Appearance Form: crystalline Colour: colourless b) Odour No data available c) Odour Threshold No data available No data available d) Melting point/freezing Melting point/range: 58 - 62 °C (136 - 144 °F) point Melting point/range: 58 - 62 °C (136 - 144 °F) Initial boiling point and No data available boiling range g) Flash point No data available h) Evaporation rate No data available Flammability (solid, gas) No data available Upper/lower No data available flammability or explosive limits

 o) Partition coefficient: noctanol/water

on coefficient: n- No data available

p) Auto-ignition temperature

No data available

q) Decomposition temperature

No data available

r) Viscosity No data available
 s) Explosive properties No data available
 t) Oxidizing properties No data available

9.2 Other safety information

No data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

Strong bases

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Oxides of phosphorus, Hydrogen fluoride

Other decomposition products - No data available

In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

No data available

Inhalation: No data available Dermal: No data available

No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

No data available

Germ cell mutagenicity

No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as

probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a

known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by OSHA.

Reproductive toxicity

No data available

No data available

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

Additional Information

RTECS: Not available

Fluoride ion can reduce serum calcium levels possibly causing fatal hypocalcemia.

Salivation, Nausea, Abdominal pain, Vomiting, Fever, Rapid respiration, Fluoride ion can reduce serum calcium levels possibly causing fatal hypocalcemia., Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin., spasm, inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, burning sensation

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION

SARA 302 Components

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

No SARA Hazards

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

1-Ethyl-3-methylimidazolium hexafluorophosphate CAS-No. Revision Date 155371-19-0

New Jersey Right To Know Components

CAS-No. Revision Date

1-Ethyl-3-methylimidazolium hexafluorophosphate 155371-19-0

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. OTHER INFORMATION

HMIS Rating

Health hazard: 0
Chronic Health Hazard: Flammability: 0
Physical Hazard 0

NFPA Rating

Health hazard: 0
Fire Hazard: 0
Reactivity Hazard: 0

Further information

Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

Preparation Information

Sigma-Aldrich Corporation Product Safety – Americas Region 1-800-521-8956

Version: 3.4 Revision Date: 02/27/2016 Print Date: 11/10/2018